A multicenter randomized study comparing 6 versus 12 months of trastuzumab in combination with dose-dense docetaxel following FEC as adjuvant treatment of women with axillary node–positive or high-risk, node-negative breast cancer overexpressing HER2.
Dimitrios Mavroudis
Consultant or Advisory Role - Roche
Honoraria - Roche
Nikolaos A. Malamos
No relevant relationships to disclose
Stylianos Kakolyris
No relevant relationships to disclose
Ioannis Boukovinas
No relevant relationships to disclose
Pavlos Papakotoulas
No relevant relationships to disclose
Nikolaos Ziras
No relevant relationships to disclose
Vassilis Georgoulias
No relevant relationships to disclose